Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Jayasindu MathiyazhaganEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-7368-2688
Christabelle RajeshEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-5211-4454
Satish SagarEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Thomas C CaffreyEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Ying HuangEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Aaron M MohsFred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-9353-5404
Benjamin J SwansonFred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Michael A HollingsworthEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Cory L BrooksDepartment of Chemistry and Biochemistry, California State University Fresno, Fresno, CA 93740, USA.ORCID 0000-0002-6745-6526
Prakash RadhakrishnanEppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0001-5314-1630
Funding
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
Pancreatic Cancer Detection ConsortiumU01CA210240 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Michael A. Hollingsworth · 2017 to 2026
$12.9M
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC MetastasisP01CA217798 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K. · 2018 to 2022
$8.1M
MUC16 in Pancreatic Cancer Progression and MetastasisR01CA208108 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI RADHAKRISHNAN, PRAKASH · 2017 to 2021
$1.7M
Targeting Disease Specific Tn Antigen in Pancreatic CancerR01CA288372 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI RICHARD D CUMMINGS, Prakash Radhakrishnan · 2025 to 2026
$1.1M
Role of Antigen Glycosylation in Mucin Binding by Monoclonal AntibodiesR15CA242349 · NCI · CALIFORNIA STATE UNIVERSITY FRESNO · PI BROOKS, CORY · 2020 to 2020
$415k
American Cancer Society Research Scholar Grant RSG-22-100-01-1278 CDPNCI NIH HHS P01 CA217798NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA208108NCI NIH HHS R01 CA288372NCI NIH HHS R15 CA242349NCI NIH HHS U01 CA210240NIH HHS 1273CA217798NIH HHS CA208108NIH HHS CA288372NIH HHS R15CA242349the Otis Glebe Foundation the Otis Glebe Foundation
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
early detectionmagnetic resonance imagingMUC16pancreatic cancer
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Humanized Anti-MUC16 Antibody-Conjugated Contrast Agents for Magnetic Resonance Imaging of Pancreatic Cancer. · full record | OpenQuestion